Neuradiant 1070 nm Helmet
The Neuradiant 1070 stimulates more of the skull including the brain stem and cerebellum, like the Cognitolite, but also provides variable duration, intensity (duty cycle), and single hertz pulse control (1-10,000hz), for more accurate stimulation protocol control and improved results.
The Quietmind Foundation along with Baylor Research Institute (BRI), an affiliate of Baylor Scott & White Health and Texas A&M School of Medicine, conducted one of the first human clinical trials using neuropsychological and advanced neuroimaging assessments to evaluate this innovative approach to transcranial PBM. The device used in that trial was the Cognitolite 1070nm wavelength, which produced rapid (<30 days), significant improvement in mood, motor, and memory loss symptoms. The Neuradiant 1070 4Q unit represents the next generation of PBM technology, based on the QMF-BRI research that can safely and reliably offer home-based, self-administered, affordable transcranial Photobiomodulation. This technology offers hope to people dealing with a wide range of symptoms associated with neurodegenerative, chronic pain, and neuropsychiatric disorders.
Published, peer-reviewed evidence indicates that 1070 nm can be effective in improving cognitive, motor, and behavioral symptoms associated with neurodegenerative disorders, eg., long-COVID, Alzheimer’s, Parkinson’s and other neurodegenerative conditions. It should be noted that the 1070nm wavelength has been recognized as evidencing disease-modifying properties in the treatment of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Lewy Body Dementia, and Frontotemporal Dementia.
